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ABSTRACT Efﬁcacy and safety of tiotropium+olodaterol ﬁxed-dose combination (FDC) compared with the
mono-components was evaluated in patients with moderate to very severe chronic obstructive pulmonary
disease (COPD) in two replicate, randomised, double-blind, parallel-group, multicentre, phase III trials.
Patients received tiotropium+olodaterol FDC 2.5/5 μg or 5/5 μg, tiotropium 2.5 μg or 5 μg, or olodaterol
5 μg delivered once-daily via Respimat inhaler over 52 weeks. Primary end points were forced expiratory
volume in 1 s (FEV1) area under the curve from 0 to 3 h (AUC0–3) response, trough FEV1 response and
St George’s Respiratory Questionnaire (SGRQ) total score at 24 weeks.
In total, 5162 patients (2624 in Study 1237.5 and 2538 in Study 1237.6) received treatment. Both FDCs
signiﬁcantly improved FEV1 AUC0–3 and trough FEV1 response versus the mono-components in both
studies. Statistically signiﬁcant improvements in SGRQ total score versus the mono-components were only
seen for tiotropium+olodaterol FDC 5/5 μg. Incidence of adverse events was comparable between the
FDCs and the mono-components.
These studies demonstrated signiﬁcant improvements in lung function and health-related quality of
life with once-daily tiotropium+olodaterol FDC versus mono-components over 1 year in patients with
moderate to very severe COPD.
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Introduction
Long-acting bronchodilators, such as long-acting muscarinic antagonists (LAMAs), are the cornerstone of
maintenance therapy for patients with moderate to very severe chronic obstructive pulmonary disease
(COPD) whose symptoms are not adequately controlled by short-acting bronchodilators alone [1, 2].
Tiotropium is an established once-daily LAMA that improves the main functional and patient-orientated
outcomes of COPD [3–8]. Tiotropium has also been demonstrated to moderate disease progression, even
in the early stages of COPD (e.g. patients not receiving maintenance therapy [9] or those with Global
initiative for chronic Obstructive Lung Disease (GOLD) stage 2 disease [10]).
The novel once-daily long-acting β2-agonist (LABA) olodaterol is a highly selective and nearly full β2
agonist [11, 12] that provides 24-h bronchodilation in patients with COPD [13–16]. Olodaterol is also
associated with symptomatic beneﬁt [17] and enhanced exercise capacity [18].
An option recommended by GOLD for patients not adequately controlled on a single long-acting
bronchodilator is to combine a LAMA with a LABA [2]. This has prompted the development of combining
LAMA+LABA as ﬁxed-dose combinations (FDCs) [1]. The complementary modes of action of tiotropium
and olodaterol have previously been demonstrated in animal models and phase II clinical trials [19–22].
We hypothesised that combination therapy with tiotropium+olodaterol FDC would provide improvements
in lung function, health-related quality of life and other COPD disease parameters compared to
monotherapy with either component alone, with a comparable safety proﬁle. These two replicate, global,
phase III trials (TOnado 1 and 2) aimed to assess the efﬁcacy and safety of once-daily treatment with
orally inhaled tiotropium+olodaterol FDC 5/5 µg or 2.5/5 µg delivered via the Respimat Soft Mist Inhaler
(Boehringer Ingelheim, Ingelheim am Rhein, Germany) compared with their individual
mono-components in patients with moderate to very severe COPD (GOLD stage 2–4) over 52 weeks.
Methods
Study design
These were multinational, replicate, phase III, multicentre, randomised, double-blind, active-controlled,
ﬁve-arm, parallel-group studies, registered with ClinicalTrials.gov (Study 1237.5: NCT01431274; Study
1237.6: NCT01431287) (ﬁg. 1). Three primary end points were evaluated after 24 weeks of treatment:
forced expiratory volume in 1 s (FEV1) area under the curve from 0 to 3 h (AUC0–3) response (in each
individual trial), trough FEV1 response in each individual trial (response deﬁned as change from baseline;
mean of the values of 1 h and 10 min prior to the ﬁrst dose of study medication); and St George’s
Respiratory Questionnaire (SGRQ) total score (SGRQ was analysed in a pre-speciﬁed combined analysis of
data from both studies). Pulmonary function tests (PFTs) were performed on day 1 and at weeks 2, 6, 12,
18, 24, 32, 40 and 52. SGRQ was completed on day 1 and after 12, 24 and 52 weeks, prior to PFTs and all
other procedures. Details of the study design, assessments performed and statistical methodology are
provided in table S1 of the online supplementary material.
Patients continued to receive treatment with inhaled corticosteroids as required and were provided with
salbutamol/albuterol metered-dose inhaler (100 μg per actuation) as rescue medication to be used as
necessary at any point during the trial. Temporary increases in the dose or addition of oral steroids or
theophylline preparations were allowed during the treatment portion of the study; PFTs were not
performed within 7 days of the last administered dose.
Patients
Patients were randomised if they met the following main inclusion criteria: outpatients aged ⩾40 years
with a history of moderate to very severe COPD (GOLD stage 2–4) [23]; post-bronchodilator FEV1 <80%
of predicted normal; post-bronchodilator FEV1/forced vital capacity (FVC) <70%; current or ex-smokers
with a smoking history of >10 pack–years.
This article has supplementary material available from erj.ersjournals.com
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Patients with a signiﬁcant disease other than COPD were excluded from the trials. Other exclusion criteria
included: clinically relevant abnormal baseline laboratory parameters or a history of asthma; myocardial
infarction within 1 year of screening; unstable or life-threatening cardiac arrhythmia; known active
tuberculosis; clinically evident bronchiectasis; cystic ﬁbrosis or life-threatening pulmonary obstruction;
hospitalised for heart failure within the past year; diagnosed thyrotoxicosis or paroxysmal tachycardia;
previous thoracotomy with pulmonary resection; regular use of daytime oxygen if patients were unable to
abstain during clinic visits; or currently enrolled in a pulmonary rehabilitation programme (or completed
in the 6 weeks before screening).
Patients with moderate or severe renal impairment (creatinine clearance ⩽50 mL·min−1) were not excluded
from the study but were closely monitored by the investigator.
Both studies were performed in accordance with the Declaration of Helsinki, International Conference on
Harmonisation Harmonised Tripartite Guideline for Good Clinical Practice and local regulations. The
protocols were approved by the authorities and the ethics committees of the respective institutions, and
signed informed consent was obtained from all patients.
Results
Patient disposition and baseline characteristics
A total of 5163 patients (2624 Study 1237.5; 2539 Study 1237.6) were randomised to receive treatment in
25 countries; 5162 patients were treated (2624 Study 1237.5; 2538 Study 1237.6). Overall, 84.6% of patients
(86.2% Study 1237.5; 83.0% Study 1237.6) completed the studies. The discontinuation rate was higher in
the monotherapy than the combination treatment groups in both studies (ﬁg. 2). The data for the
individual studies are presented in the online supplementary material.
Baseline demographics were generally similar across treatment groups. The majority of patients were male
(72.9% total) and approximately one-third were current smokers. Most patients were classiﬁed as GOLD
stage 2/3 (88.6%); the remaining patients (11.3%) were classiﬁed as GOLD stage 4. Overall, 86.4% of
patients had diagnosed co-morbidities at baseline; 1107 (21.4%) had cardiac disorders and 2481 (48.1%)
had vascular disorders including hypertension (table 1, and table S2 in the online supplementary material
for individual study data).
Efﬁcacy
Lung function
FEV1 AUC0–3 responses for tiotropium+olodaterol FDC 2.5/5 μg, 5/5 μg, tiotropium 2.5 μg, 5 μg and
olodaterol 5 μg were 241, 256, 148, 139 and 133 mL, respectively, in Study 1237.5, and 256, 268, 125, 165 and
136 mL, respectively, in Study 1237.6. Improvements in adjusted mean FEV1 AUC0–3 with tiotropium
+olodaterol FDC 5/5 µg and 2.5/5 µg over the corresponding individual components in the individual studies
and the combined analysis were statistically signiﬁcant (p<0.0001 for all comparisons) (table 2, and table S3 in
the online supplementary material). The comparison of tiotropium+olodaterol FDC 2.5/5 μg with tiotropium
5 μg (performed to compare the combination with the licensed tiotropium dose) was p<0.0001 for all analyses.
Trough FEV1 responses after 24 weeks for tiotropium+olodaterol FDC 2.5/5 μg, 5/5 μg, tiotropium 2.5 μg,
5 μg and olodaterol 5 μg were 111, 136, 83, 65 and 54 mL, respectively, in Study 1237.5, and 125, 145, 62,
96 and 57 mL, respectively, in Study 1237.6. Improvements in the adjusted mean trough FEV1 with
Tiotropium+olodaterol 
FDC Respimat 5/5 µg once daily
Tiotropium+olodaterol 
FDC Respimat 2.5/5 µg once daily
Olodaterol Respimat 
5 µg once daily
Tiotropium Respimat 
5 µg once daily
Tiotropium Respimat
2.5 µg once daily
S
C
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FIGURE 1 Study design (Study 1237.5:
NCT01431274; Study 1237.6: NCT0143
1287). R: randomisation; FDC: ﬁxed-
dose combination. #: primary end-point
assessment.
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tiotropium+olodaterol FDC 5/5 µg and 2.5/5 µg over the corresponding individual components in both the
individual studies and the combined data were statistically signiﬁcant (p<0.05 for all comparisons)
(table 2, and table S3 in the online supplementary material).
3369 screeneda)
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Treated set
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Tio + Olo FDC Respimat
5/5 µg once daily
Treated set
n=507
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study medication:
  59 Adverse events
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FIGURE 2 Patient disposition and ﬂow in (a) Study 1237.5 and (b) Study 1237.6. Tio: tiotropium; Olo: olodaterol; FDC: ﬁxed-dose combination. #: not due to
adverse event.
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There was no inﬂuence of sex on either FEV1 AUC0–3 or trough FEV1 response. An analysis of FEV1
AUC0–3 and trough FEV1 response according to baseline disease severity showed that responses were
lower in patients with more severe disease (table S4 in the online supplementary material).
An analysis of FEV1 AUC0–3 and trough FEV1 according to inhaled corticosteroid use is presented in
table 3. This conﬁrms that tiotropium+olodaterol improves lung function whether patients were receiving
inhaled corticosteroid or not.
Improvements were observed for FEV1 values on all test days over each of the 52-week studies (ﬁg. 3a and b,
and ﬁg. S1 in the online supplementary material). Responses in trough FVC and FVC AUC0–3 over 24 weeks
of treatment were in line with the primary end points (table S5 in the online supplementary material).
Health status and symptomatic beneﬁt
After 24 weeks, the pre-speciﬁed analysis of the adjusted mean SGRQ total score (table 4) revealed
statistically signiﬁcant improvements for tiotropium+olodaterol FDC 5/5 µg over corresponding individual
components (versus olodaterol 5 µg: −1.693 (0.553), p<0.01; versus tiotropium 5 µg: −1.233 (0.551),
p<0.05) but not for tiotropium+olodaterol FDC 2.5/5 µg versus the individual components (table 5).
Responder rates for SGRQ total scores after 24 weeks for the combined data set (responders deﬁned as
decrease in SGRQ total score ⩾4.0 units, minimum clinically important difference) were: tiotropium
TABLE 1 Demographic and baseline patient characteristics (treated population): combined data (n=5162)
Olodaterol
5 µg
Tiotropium
2.5 µg
Tiotropium
5 µg
Tiotropium+olodaterol
2.5/5 µg
Tiotropium+olodaterol
5/5 µg
Participants n 1038 1032 1033 1030 1029
Male 764 (73.6) 753 (73.0) 755 (73.1) 757 (73.5) 733 (71.2)
Age years 64.2±8.2 64.0±8.7 63.9±8.6 64.1±7.8 63.8±8.3
Smoking status
Ex-smoker 660 (63.6) 644 (62.4) 663 (64.2) 658 (63.9) 629 (61.1)
Current smoker 378 (36.4) 388 (37.6) 370 (35.8) 372 (36.1) 400 (38.9)
Co-morbidities 897 (86.4) 884 (85.7) 902 (87.3) 889 (86.3) 890 (86.5)
Cardiac 234 (22.5) 212 (20.5) 219 (21.2) 229 (22.2) 213 (20.7)
Vascular 511 (49.2) 475 (46.0) 513 (49.7) 486 (47.2) 496 (48.2)
Pre-bronchodilator screening FEV1 mL 1209±505 1218±489 1200±504 1208±473 1180±493
Post-bronchodilator screening FEV1 mL 1377±520 1393±511 1370±521 1385±496 1344±505
Change from pre- to
post-bronchodilator FEV1 mL
168±143 174±150 171±146 177±138 164±148
FEV1/FVC % 45.0±11.6 45.1±11.6 45.0±12.0 44.6±11.5 45.1±11.6
FEV1 % predicted 50.3±15.6 50.3±15.0 49.7±15.7 50.2±14.9 49.3±15.3
GOLD stage#
1 (FEV1 ⩾80% pred) 0 (0.0) 1 (0.1) 1 (0.1) 1 (0.1) 0 (0.0)
2 (FEV1 50–<80% pred) 532 (51.3) 518 (50.2) 517 (50.0) 519 (50.4) 502 (48.8)
3 (FEV1 30–<50% pred) 378 (36.4) 409 (39.6) 387 (37.5) 407 (39.5) 408 (39.7)
4 (FEV1 <30% pred) 128 (12.3) 103 (10.0) 128 (12.4) 103 (10.0) 119 (11.6)
Baseline pulmonary medication
SAMA¶ 134 (12.9) 140 (13.6) 131 (12.7) 135 (13.1) 125 (12.1)
LAMA+ 365 (35.2) 348 (33.7) 346 (33.5) 403 (39.1) 378 (36.7)
SABA§ 424 (40.8) 433 (42.0) 401 (38.8) 421 (40.9) 400 (38.9)
LABAƒ 491 (47.3) 475 (46.0) 450 (43.6) 491 (47.7) 486 (47.2)
ICS## 505 (48.7) 476 (46.1) 466 (45.1) 493 (47.9) 506 (49.2)
Xanthines¶¶ 96 (9.2) 94 (9.1) 109 (10.6) 109 (10.6) 108 (10.5)
Baseline cardiovascular medication 620 (59.7) 580 (56.2) 596 (57.7) 599 (58.2) 581 (56.5)
β-blockers 102 (9.8) 119 (11.5) 109 (10.6) 117 (11.4) 110 (10.8)
Data are presented as n (%) or mean±SD, unless otherwise stated. FEV1: forced expiratory volume in 1 s; FVC: forced vital capacity; GOLD:
Global initiative for chronic Obstructive Lung Disease; SAMA: short-acting muscarinic antagonist; LAMA: long-acting muscarinic antagonist;
SABA: short-acting β-agonist; LABA: long-acting β2-agonist; ICS: inhaled corticosteroid.
#: based on post-bronchodilator FEV1 percentage
predicted. In Study 1237.6, 1 patient on tiotropium 2.5 µg was not categorised; ¶: ipratropium, ipratropium/fenoterol or ipratropium/salbutamol,
oxitropin; +: tiotropium; §: all patients received SABAs as rescue medication; ƒ: including arformoterol, formoterol, indacaterol, fenoterol and
salmeterol; ##: including beclomethasone, budesonide, ciclesonide, mometasone furoate/formoterol fumarate hihydrate, fluticasone,
formoterol/beclomethasone, formoterol/budesonide, mometasone, mometasone furoate, salmeterol/fluticasone; ¶¶: including aminophylline,
theophylline.
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+olodaterol FDC 5/5 µg, 57.5%; tiotropium+olodaterol FDC 2.5/5 µg, 53.2%, and responder rates of 49.6%,
48.7% and 44.8% for tiotropium 2.5 µg, 5 µg and olodaterol 5 µg, respectively. The increases in responder
rate for tiotropium+olodaterol FDC 5/5 µg over its individual components were statistically signiﬁcant
(nominal p<0.05), and for tiotropium+olodaterol FDC 2.5/5 µg there was a signiﬁcant improvement in
responder rate versus olodaterol 5 µg and tiotropium 5 µg but not tiotropium 2.5 µg (table 5).
The pre-speciﬁed analysis of the key secondary end point (Mahler Transition Dyspnoea Index focal score at
24 weeks (combined data set)) showed statistically signiﬁcant improvements for both tiotropium+olodaterol
FDCs versus their mono-components (nominal p<0.05) (table S6 in the online supplementary material).
Rescue medication
Both tiotropium+olodaterol FDC 5/5 µg and 2.5/5 µg provided reductions in adjusted weekly mean daily
(24-h) rescue medication use compared to the monotherapy components throughout the 52-week
treatment period (ﬁg. S2 in the online supplementary material).
Exacerbations
Figure S3 in the online supplementary material shows Kaplan–Meier estimates of probability of moderate/
severe COPD exacerbation. There was a trend for improvement in exacerbations with both FDCs versus
the monotherapy components.
Safety
Table 6 shows a summary of adverse events for the combined data set (for Studies 1237.5 and 1237.6, see
table S7 in the online supplementary material). Adverse event incidence was generally balanced across all
treatment groups, with the majority being mild to moderate in severity. The proportion of patients who
TABLE 2 FEV1 AUC0–3 and trough FEV1 responses (i.e. change from baseline) after 24 weeks of treatment (full analysis set) in Studies 1237.5
and 1237.6 separately
Treatment comparison FEV1 AUC0–3# L p-value Trough FEV1¶ L p-value
Study 1237.5 common study baseline 1.158±0.010 1.161±0.010
Tiotropium+olodaterol 5/5 µg
versus olodaterol 5 µg 0.123±0.012 (0.100–0.146) <0.0001 0.082±0.012 (0.059–0.106) <0.0001
versus tiotropium 5 µg 0.117±0.012 (0.094–0.140) <0.0001 0.071±0.012 (0.047–0.094) <0.0001
Tiotropium+olodaterol 2.5/5 µg
versus olodaterol 5 µg 0.109±0.012 (0.086–0.132) <0.0001 0.058±0.012 (0.034–0.081) <0.0001
versus tiotropium 2.5 µg 0.093±0.012 (0.070–0.116) <0.0001 0.029±0.012 (0.005–0.052) 0.0174
versus tiotropium 5 µg 0.102±0.012 (0.080–0.125) <0.0001 0.046±0.012 (0.023–0.070) 0.0001
Tiotropium+olodaterol 5/5 µg
versus tiotropium+olodaterol 2.5/5 µg 0.014±0.012 (-0.008–0.037) 0.2169 0.024±0.012 (0.001–0.048) 0.0407
Study 1237.6 common study baseline 1.150±0.010 1.150±0.010
Tiotropium+olodaterol 5/5 µg
versus olodaterol 5 µg 0.132±0.013 (0.108–0.157) <0.0001 0.088±0.013 (0.063–0.113) <0.0001
versus tiotropium 5 µg 0.103±0.012 (0.078–0.127) <0.0001 0.050±0.013 (0.024–0.075) 0.0001
Tiotropium+olodaterol 2.5/5 µg
versus olodaterol 5 µg 0.121±0.012 (0.096–0.145) <0.0001 0.067±0.013 (0.042–0.092) <0.0001
versus tiotropium 2.5 µg 0.131±0.012 (0.106–0.155) <0.0001 0.062±0.013 (0.037–0.087) <0.0001
versus tiotropium 5 µg 0.091±0.012 (0.066–0.115) <0.0001 0.029±0.013 (0.004–0.054) 0.0231
Tiotropium+olodaterol 5/5 µg
versus tiotropium+olodaterol 2.5/5 µg 0.012±0.012 (-0.013–0.036) 0.3394 0.021±0.013 (-0.004–0.046) 0.1073
Data are presented as adjusted mean±SE (95% CI), unless otherwise stated. Adjusted means were obtained from fitting a mixed model for
repeated measurements, including fixed effects of treatment, planned test day, treatment-by-test-day interaction, baseline and
baseline-by-test-day interaction; patient as a random effect; spatial power covariance structure for within-patient errors and Kenward−Roger
approximation of denominator degrees of freedom. FEV1: forced expiratory volume in 1 s; AUC0–3: area under the curve from 0 to 3 h.
#: number of patients contributing to the mixed model for repeated measurements for adjusted mean FEV1 AUC0–3 Study 1237.5: tiotropium
+olodaterol 5/5 μg n=522, tiotropium+olodaterol 2.5/5 μg n=521, tiotropium 5 μg n=526, tiotropium 2.5 μg n=524, olodaterol 5 μg n=525; Study
1237.6: tiotropium+olodaterol 5/5 μg n=502, tiotropium+olodaterol 2.5/5 μg n=506, tiotropium 5 μg n=500, tiotropium 2.5 μg n=504, olodaterol
5μg n=507. ¶: number of patients contributing to the mixed model for repeated measurements for adjusted mean trough FEV1 Study 1237.5:
tiotropium+olodaterol 5/5 μg n=521, tiotropium+olodaterol 2.5/5 μg n=518, tiotropium 5 μg n=520, tiotropium 2.5 μg n=519, olodaterol 5 μg
n=519; Study 1237.6: tiotropium+olodaterol 5/5 μg n=497, tiotropium+olodaterol 2.5/5 μg n=500, tiotropium 5 μg n=498, tiotropium 2.5 μg n=499,
olodaterol 5 μg n=503.
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reported at least one adverse event while on treatment was 74.4%. Overall, 6.4% of adverse events were
deemed treatment related; rates of serious adverse events were broadly similar across treatment arms. Rates
of serious adverse events were 16.4%, with fatality rates of 1.5%. The majority of treatment-emergent
adverse events (incidence of >3%) were respiratory events, in particular COPD exacerbations and
infections according to Medical Dictionary for Regulatory Activities (MedDRA) classiﬁcations. A higher
proportion of patients in the tiotropium+olodaterol FDC 2.5/5 µg arm experienced upper respiratory
infections while on treatment compared with the other arms. Respiratory events (including COPD
exacerbations) were more frequent among patients treated with monotherapies. No signiﬁcant
abnormalities in vital signs or laboratory parameters were observed in either study.
TABLE 3 FEV1 AUC0–3 and trough FEV1 responses (i.e. change from baseline) after 24 weeks of treatment by ICS usage (full analysis set,
combined data)
Treatment comparison ICS usage
Yes No
Adjusted mean±SE (95% CI) p-value Adjusted mean±SE (95% CI) p-value
FEV1 AUC0–3L
Common study baseline 1.073±0.009 1.226±0.010
Tiotropium+olodaterol 5/5 µg
versus olodaterol 5 µg 0.131±0.012 (0.107–0.154) <0.0001 0.125±0.012 (0.101–0.148 <0.0001
versus tiotropium 5 µg 0.113±0.012 (0.089–0.137) <0.0001 0.108±0.012 (0.085–0.132) <0.0001
Tiotropium+olodaterol 2.5/5 µg
versus olodaterol 5 µg 0.117±0.012 (0.093–0.141) <0.0001 0.113±0.012 (0.090–0.137) <0.0001
versus tiotropium 2.5 µg 0.104±0.012 (0.080–0.128) <0.0001 0.120±0.012 (0.096–0.143) <0.0001
versus tiotropium 5 µg 0.099±0.012 (0.075–0.123) <0.0001 0.097±0.012 (0.074–0.120) <0.0001
Tiotropium+olodaterol 5/5 µg
versus tiotropium+olodaterol 2.5/5 µg 0.014±0.012 (–0.010–0.037) 0.2533 0.012±0.012 (–0.012–0.035) 0.3342
Trough FEV1L
Common study baseline 1.075±0.009 1.227±0.010
Tiotropium+olodaterol 5/5 µg
versus olodaterol 5 µg 0.087±0.012 (0.063–0.111) <0.0001 0.082±0.013 (0.057–0.107) <0.0001
versus tiotropium 5 µg 0.045±0.012 (0.021–0.070) 0.0003 0.076±0.012 (0.052–0.100) <0.0001
Tiotropium+olodaterol 2.5/5 µg
versus olodaterol 5 µg 0.068±0.012 (0.044–0.092) <0.0001 0.056±0.013 (0.031–0.080) <0.0001
versus tiotropium 2.5 µg 0.030±0.012 (0.006–0.055) 0.0155 0.060±0.012 (0.036–0.084) <0.0001
versus tiotropium 5 µg 0.026±0.013 (0.001–0.050) 0.0385 0.050±0.012 (0.025–0.074) <0.0001
Tiotropium+olodaterol 5/5 µg
versus tiotropium+olodaterol 2.5/5 µg 0.019±0.012 (−0.005–0.043) 0.1134 0.026±0.013 (0.002–0.051) 0.0369
FEV1: forced expiratory volume in 1 s; AUC0–3: area under the curve from 0 to 3 h; ICS: inhaled corticosteroid.
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FIGURE 3 Lung function end points (combined data set) over 52 weeks: full analysis set. a) adjusted mean trough
forced expiratory volume in 1 s (FEV1); all comparisons of Tio+Olo 5/5 μg and 2.5/5 μg versus the monotherapies were
statistically signiﬁcant (p<0.05) with the exception of Tio+Olo 2.5/5 μg versus Tio 2.5 μg at day 43. b) FEV1 area under
the curve from 0 to 3 h (AUC0–3); all comparisons of Tio+Olo 5/5 μg and 2.5/5 μg versus the monotherapies were
statistically signiﬁcant (p<0.01). Tio: tiotropium; Olo: olodaterol.
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Overall incidence of adverse events in the subset of patients with cardiac history was broadly comparable
(78.1%, 75.8%, 79.0%, 80.6% and 79.7% in the tiotropium+olodaterol FDC 5/5 µg, tiotropium+olodaterol
FDC 2.5/5 µg, tiotropium 2.5 µg, 5 µg and olodaterol 5 µg groups, respectively). Rate ratios for
major adverse cardiac events (MACE) and “cardiac disorders” System Organ Class (SOC) are presented in
table S8 of the online supplementary material, which demonstrates that the incidences of these events were
similar with the FDCs and individual components.
Discussion
This pair of replicate, 52-week studies of the effects of once-daily combination of tiotropium+olodaterol
administered via the Respimat Soft Mist Inhaler in patients with moderate to very severe COPD conﬁrm
statistically signiﬁcant increases for the primary lung-function end points of trough FEV1 and FEV1
AUC0–3 response after 24 weeks versus either tiotropium or olodaterol alone. These results are supported
by a range of secondary lung-function end points over 52 weeks. FEV1 AUC0–3 and trough FEV1 reﬂect
bronchodilator beneﬁt at the beginning and end of a 24-h cycle and are important measures in the
selection of optimum doses and dosing frequency.
Long-acting bronchodilators remain the cornerstone of COPD maintenance therapy [2]. However, the
combination of bronchodilators with different modes of action has not been commonly prescribed in
TABLE 4 St George’s Respiratory Questionnaire (SGRQ) score at 24 weeks (full analysis set)
SGRQ total score# SGRQ responders¶
Studies 1237.5+1237.6 common study baseline 43.512±0.259
Olodaterol 5 µg 38.366±0.396 427/954 (44.8)
Tiotropium 2.5 µg 37.792±0.390 476/960 (49.6)
Tiotropium 5 µg 37.907±0.393 465/955 (48.7)
Tiotropium+olodaterol 2.5/5 µg 37.335±0.385 527/990 (53.2)
Tiotropium+olodaterol 5/5 µg 36.674±0.386 563/979 (57.5)
Data are presented as adjusted mean±SE or n/N (%). Data were obtained from fitting a mixed model for
repeated measurements including fixed effects of treatment, planned test day, treatment-by-test-day
interaction, baseline and baseline-by-test-day interaction; patient as a random effect; spatial power
covariance structure for within-patient errors and Kenward−Roger approximation of denominator degrees of
freedom. #:number of patients contributing to the mixed model for repeated measurements for adjusted
mean SGRQ across both studies: tiotropium+olodaterol 5/5 μg n=979; tiotropium+olodaterol 2.5/5 μg n=990;
tiotropium 5 μg n=954; tiotropium 2.5 μg n=960; olodaterol 5 μg n=954; ¶: defined as having an SGRQ total
score at week 24⩾4.0-times better than baseline SGRQ total score.
TABLE 5 St George’s Respiratory Questionnaire (SGRQ) score at 24 weeks (full analysis set): treatment comparisons
Treatment comparison SGRQ total score# p-value Responder analysis¶ odds ratio§, ƒ p-value
Tiotropium+olodaterol 5/5 µg
versus olodaterol 5 µg −1.693±0.553 (−2.778–−0.608) 0.0022 1.670±0.153 (1.395–1.999) <0.0001
versus tiotropium 5 µg −1.233±0.551 (−2.313–−0.153) 0.0252 1.426±0.131 (1.192–1.706) 0.0001
Tiotropium+olodaterol 2.5/5 µg
versus olodaterol 5 µg −1.031±0.552 (−2.113–0.052) 0.0620 1.405±0.128 (1.175–1.679) 0.0002
versus tiotropium 2.5 µg −0.456±0.548 (−1.531–0.618) 0.4051 1.157±0.105 (0.969–1.383) 0.1071
versus tiotropium 5 µg −0.571±0.550 (−1.649–0.507) 0.2988 1.199±0.109 (1.004–1.433) 0.0453
Tiotropium+olodaterol 5/5 µg
versus tiotropium+olodaterol 2.5/5 µg −0.662±0.545 (−1.731–0.407) 0.2249 1.189±0.108 (0.995–1.421) 0.0565
Data are presented as adjusted mean±se, unless otherwise stated. Data were obtained from fitting a mixed model for repeated measurements
including fixed effects of treatment, planned test day, treatment-by-test-day interaction, baseline and baseline-by-test-day interaction; patient
as a random effect; spatial power covariance structure for within-patient errors and Kenward−Roger approximation of denominator degrees of
freedom. #:number of patients contributing to the mixed model for repeated measurements for adjusted mean SGRQ across both studies:
tiotropium+olodaterol 5/5 μg n=979; tiotropium+olodaterol 2.5/5 μg n=990; tiotropium 5 μg n=954; tiotropium 2.5 μg n=960; olodaterol 5 μg
n=954; ¶: defined as having an SGRQ total score at week 24⩾4.0-times better than baseline SGRQ total score.§: responder analysis results are
from fitting a logistic-regression model with treatment as covariate and a logit link function; ƒ: number of patients contributing to SGRQ
responder analysis across both studies: tiotropium+olodaterol 5/5 μg n=979; tiotropium+olodaterol 2.5/5 μg n=990; tiotropium 5 μg n=955;
tiotropium 2.5 μg n=960; olodaterol 5 μg n=954.
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clinical practice [1] due, in part, to the lack, until recently, of available FDCs of LAMA+LABA. Olodaterol
is a novel once-daily LABA that has been designed as a combination partner for tiotropium, with
matching pharmacokinetic and pharmacodynamic proﬁles [11]. Initial results have indicated that
olodaterol may augment the beneﬁcial effects of tiotropium in patients with COPD [21, 22].
The results of our trial are broadly similar with those reported for other LAMA+LAMA FDCs [24–26].
However, comparisons between trials are inadvisable owing to differences in study design, including
duration and patient population. Compared with those performed with indacaterol/glycopyrronium [24,
25], our studies included a higher proportion of patients with severe or very severe COPD; the fact that, in
general, patients with lower lung function show smaller responses to treatment in clinical trials may
explain why the increases with dual bronchodilator treatment were slightly lower. An earlier study with the
FDC of tiotropium+olodaterol that included fewer patients with very severe disease showed larger effect
sizes than the current studies [27].
Symptomatic beneﬁt of the FDC was demonstrated by statistically signiﬁcant improvements in mean
SGRQ total score; compared with monotherapy, this was observed with tiotropium+olodaterol FDC 5/5 μg
but not with 2.5/5 μg. Improvements in SGRQ that exceeded the minimum clinically important difference
of 4 units for this measure were seen in all treatment arms, but the difference between the FDCs and the
monotherapies did not meet this threshold [28]. Since there was no placebo arm, further analysis of the
relevance of these improvements is limited. Responder analyses have been proposed as an additional
approach to assessing efﬁcacy of treatments in COPD, particularly for studies in which second and third
TABLE 6 Summary of adverse events: combined analysis (treated set)
Olodaterol
5 µg
Tiotropium
2.5 µg
Tiotropium
5 µg
Tiotropium+olodaterol
2.5/5 µg
Tiotropium+olodaterol
5/5 µg
Patients n 1038 1032 1033 1030 1029
All adverse events 795 (76.6) 758 (73.4) 757 (73.3) 769 (74.7) 761 (74.0)
Treatment-related adverse
events
69 (6.6) 62 (6.0) 63 (6.1) 62 (6.0) 73 (7.1)
Adverse events leading to
discontinuation
103 (9.9) 90 (8.7) 93 (9.0) 57 (5.5) 76 (7.4)
Serious adverse events 181 (17.4) 156 (15.1) 172 (16.7) 168 (16.3) 169 (16.4)
Fatal 14 (1.3) 12 (1.2) 17 (1.6) 14 (1.4) 18 (1.7)
Life-threatening 3 (0.3) 5 (0.5) 2 (0.2) 5 (0.5) 5 (0.5)
Disabling/incapacitating 1 (0.1) 3 (0.3) 2 (0.2) 0 (0.0) 3 (0.3)
Requiring hospitalisation 162 (15.6) 144 (14.0) 155 (15.0) 149 (14.5) 153 (14.9)
Prolonging hospitalisation 12 (1.2) 10 (1.0) 3 (0.3) 7 (0.7) 6 (0.6)
Other 20 (1.9) 16 (1.6) 18 (1.7) 18 (1.7) 12 (1.2)
Specific adverse events with
an incidence >3%
Respiratory, thoracic and
mediastinal disorders
470 (45.3) 453 (43.9) 441 (42.7) 393 (38.2) 405 (39.4)
COPD 370 (35.6) 352 (34.1) 340 (32.9) 301 (29.2) 332 (32.3)
Cough 31 (3.0) 46 (4.5) 45 (4.4) 43 (4.2) 40 (3.9)
Dyspnoea 38 (3.7) 44 (4.3) 51 (4.9) 37 (3.6) 39 (3.8)
Infections and infestations 393 (37.9) 363 (35.2) 348 (33.7) 394 (38.3) 374 (36.3)
Nasopharyngitis 131 (12.6) 123 (11.9) 121 (11.7) 134 (13.0) 128 (12.4)
Upper respiratory tract
infection
56 (5.4) 61 (5.9) 57 (5.5) 69 (6.7) 54 (5.2)
Pneumonia 36 (3.5) 24 (2.3) 26 (2.5) 31 (3.0) 34 (3.3)
Bronchitis 33 (3.2) 23 (2.2) 23 (2.2) 28 (2.7) 31 (3.0)
Gastrointestinal disorders 165 (15.9) 152 (14.7) 154 (14.9) 146 (14.2) 143 (13.9)
Diarrhoea 33 (3.2) 23 (2.2) 27 (2.6) 29 (2.8) 24 (2.3)
Musculoskeletal and
connective tissue disorders
124 (11.9) 119 (11.5) 117 (11.3) 155 (15.0) 156 (15.2)
Back pain 35 (3.4) 23 (2.2) 19 (1.8) 40 (3.9) 37 (3.6)
Nervous system disorders 87 (8.4) 93 (9.0) 101 (9.8) 100 (9.7) 84 (8.2)
Headache 31 (3.0) 23 (2.2) 41 (4.0) 30 (2.9) 27 (2.6)
Vascular disorders 72 (6.9) 54 (5.2) 50 (4.8) 58 (5.6) 62 (6.0)
Hypertension 48 (4.6) 28 (2.7) 30 (2.9) 35 (3.4) 30 (2.9)
Data are presented as n (%), unless otherwise stated. COPD: chronic obstructive pulmonary disease.
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treatments are added to current therapy [28]. In our studies, responder rates, deﬁned as a reduction in
SGRQ total score of ⩾4 units from baseline, were signiﬁcantly greater for tiotropium+olodaterol FDC
5/5 μg compared with its monotherapy components and for 2.5/5 µg compared with olodaterol 5 µg.
The doses of tiotropium and olodaterol used in these studies were based on previously published dose–
response studies of this drug combination [21, 22]. In the latter, although a dose response for lung
function was observed with increasing doses of tiotropium added to a ﬁxed dose of olodaterol, the increase
with tiotropium 2.5 µg when added to olodaterol was smaller than the increase with 5 µg when added to
olodaterol [21, 22]. Overall, based on the results of the current studies and TIOSPIR, the optimum dose of
tiotropium is considered to be 5 µg, both as monotherapy and in combination with olodaterol.
The assessment of safety in our studies yielded no speciﬁc concerns in spite of the inclusion of a relatively
large proportion of patients with GOLD stage 4 disease and a substantial proportion with co-morbidities.
The number of adverse events in the arms with tiotropium+olodaterol FDCs were not higher than in those
receiving the individual components; there was also no difference in incidence of adverse events with the
higher and lower doses of tiotropium.
“Dry mouth” (typically associated with LAMAs) was reported as a side effect in <2% of patients, possibly
attributable to the fact that the majority of patients included in these trials had previously received
tiotropium. Additionally, there appears to be no increase in risk of experiencing either a MedDRA SOC
“cardiac” or MACE with tiotropium+olodaterol FDC versus the mono-components, and no imbalances
between treatment groups were seen in the subgroup of patients with a history of cardiac disease.
Our studies have several limitations. Firstly, there was no placebo group; it was considered inappropriate to
deny patients with symptomatic COPD the use of even one long-acting bronchodilator in a study lasting
1 year. Furthermore, these studies were not designed to assess the impact of tiotropium+olodaterol on
COPD exacerbations. However, the limited exacerbation data from these studies are encouraging and in
line with results for other LAMA+LABA combinations [25]. Further studies powered to examine this end
point are planned.
Conclusions
These replicate studies conﬁrm the efﬁcacy and safety of once-daily dosing with tiotropium+olodaterol
FDC as maintenance therapy in patients with moderate to very severe COPD (GOLD stage 2–4). The ﬁxed
dose of 5 μg of each appears to be optimal in the combination, providing signiﬁcant improvement in all
three primary end points (trough FEV1, FEV1 AUC0–3 and health status) compared to tiotropium or
olodaterol administered alone.
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